Abstract: The invention is related to phosphorus substituted compounds with activity for treating metabolic diseases and/or disorders, e.g., diabetes and hypercholesterolemia, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The invention is related to compounds of Formula I: or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Abstract: The invention is related to compounds of Formula I: or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Abstract: Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. A1 and A2 are moieties forming a five, six, or seven membered ring. L is a bond or a linker connecting a ring atom of Ar to N. X is O, S, or substituted nitrogen. Ar is aryl or heteroaryl, Q is N, +NR, or CR4. The aryl carbons may be independently substituted with substituents other than hydrogen. The compounds may include prodrug moieties covalently attached at any site.

Abstract: A gas stream containing nitrous oxide and ammonia is contacted with a catalyst composition containing a zeolite. N2O is reduced to N2 and H2O at low temperatures in a highly efficient manner. Ammonia-mediated reduction of nitrous oxide can be effectuated from gas streams having N2O concentrations as low as 1%. The gas stream may also contact a catalytic composition selective for the reduction of NOx. In this way, N2O and NOx treatment may be effectuated in a single process stream.

Abstract: The invention is related to phosphonate substituted compounds having immuno-modulatory activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: Phosphorus-substituted imidazole compounds with anti-HIV properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit reverse transcriptase activity and are useful therapeutically for the inhibition of such enzymes, as well as in assays for the detection of such enzymes.

Abstract: The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: A gas stream containing nitrous oxide and ammonia is contacted with a catalyst composition containing a zeolite. N2O is reduced to N2 and H2O at low temperatures in a highly efficient manner. Ammonia-mediated reduction of nitrous oxide can be effectuated from gas streams having N2O concentrations as low as 1%. The gas stream may also contact a catalytic composition selective for the reduction of NOx. In this way, N2O and Nx treatment may be effectuated in a single process stream.

Abstract: The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The invention is related to phosphorus substituted purine nucleoside phosphorylase inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The invention is related to phosphorus substituted IMPDH inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The invention is related to phosphorus substituted kinase inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The invention is related to phosphorus substituted compounds with activity for treating metabolic diseases and/or disorders, e.g., diabetes and hypercholesterolemia, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: A stabilized metal promoted aluminosilicate zeolite, useful in the selective catalytic reduction of nitrogen oxides with ammonia, having a silica to alumina mole ratio of at least 8 and less than 30 and an FT-IR absorption peak at 3781 plus or minus 2 cm?1 which stabilizes the zeolite against further dealumination such as under oxidizing and harsh hydrothermal conditions.

Abstract: Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. A1 and A2 are moieties forming a five, six, or seven membered ring. L is a bond or a linker connecting a ring atom of Ar to N. X is O, S, or substituted nitrogen. Ar is aryl or heteroaryl. Q is N, +NR, or CR4. The aryl carbons may be independently substituted with substituents other than hydrogen. The compounds may include prodrug moieties covalently attached at any site.

Abstract: The present invention is directed to an iron-promoted zeolite beta catalyst useful in the selective catalytic reduction of nitrogen oxides with ammonia in which the iron-promoted zeolite beta is treated so as to provide increased amounts of the iron promoter in the form of Fe(OH). The stabilized zeolite is formed by cation exchange of an iron salt into a zeolite beta which has a reduced sodium content such as by exchanging a sodium beta with ammonium or hydrogen cations. A zeolite beta having a reduced carbon content and a Si/Al ratio of no more than 10 also increases the Fe(OH) content of the iron-promoted catalyst. The iron-promoted catalyst which has the iron in the form of Fe(OH) is characterized by a peak at 3680±5 cm?1 in the IR spectra.

Abstract: The present invention is directed to a metal-promoted zeolite beta catalyst useful in the selective catalytic reduction of nitrogen oxides with ammonia in which the zeolite beta is pre-treated so as to provide the zeolite with improved hydrothermal stability. The stabilized beta zeolite is provided by incorporating into the zeolite structure non-framework aluminum oxide chains. The aluminum oxide chains can be incorporated into the zeolite structure by a unique steaming regimen or by treatment with rare earth metals, such as cerium. The treatment process is unlike well-known methods of dealuminizing zeolites for the purpose of increasing the silica to alumina ratio. In the present invention, the non-framework aluminum oxide is characterized by FT-IR by a peak at 3781±2 cm?1, which when present, stabilizes the zeolite against further dealumination such as under oxidizing and harsh hydrothermal conditions.

Abstract: Compounds of the formula which are useful in disease conditions mediated by TNF-?, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Abstract: The present invention relates to the three dimensional structure of human collagenase 3 (MMP-13), as well as to (i) methods of using the MMP-13 structure to rationally design or identify compounds or molecules that inhibit or activate MMP-13 activity, and (ii) compounds identified using said methods.